Fremanezumab

Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines. It is given by subcutaneous injection (injection under the skin). The most common side effect is pain and redness at the site of injection. Other side effects include allergic reactions. It is a calcitonin gene-related peptide antagonist. It was approved for medical use in the United States in 2018, the European Union in 2019, the United Kingdom in 2020, and Argentina by September 2021. Fremanezumab is indicated for the preventive treatment of migraine in adults; and the preventive treatment of episodic migraine in children who are aged 6 to 17 years of age and who weigh 45 kilograms (99 lb) or more. Fremanezumab was shown to be effective in adults with four or more attacks per month. The most common adverse reactions are located at the injection site, which occurred in 43 to 45% of people in studies (as compared to 38% under placebo). Hypersensitivity reactions occurred in fewer than 1% of patients.